A year end update led to a c 5% reduction in our FY17 PBT expectation. More detail on trading performance will emerge with the FY17 results due on 31 January and we will review our group estimates fully at that time. Investors will look for signs of trading stability and prospective cash generation, while eyeing a dividend yield of c 6%. The search for a new CEO is unlikely to have concluded by then, in our view; the role is being covered in the short term by an experienced existing NED.
Written by
Low & Bonar |
Slightly softer end to FY17 |
Trading update |
Construction & materials |
3 January 2018 |
Share price performance
Business description
Next events
Analyst
Low & Bonar is a research client of Edison Investment Research Limited |
|||||||||||||||||||||||||||||||||||||||||||||
A year end update led to a c 5% reduction in our FY17 PBT expectation. More detail on trading performance will emerge with the FY17 results due on 31 January and we will review our group estimates fully at that time. Investors will look for signs of trading stability and prospective cash generation, while eyeing a dividend yield of c 6%. The search for a new CEO is unlikely to have concluded by then, in our view; the role is being covered in the short term by an experienced existing NED.
Year end |
Revenue (£m) |
PBT* |
EPS* |
DPS |
P/E |
Yield |
11/15 |
362.1 |
27.4 |
5.8 |
2.8 |
9.6 |
5.2 |
11/16 |
402.2 |
29.2 |
6.0 |
3.0 |
8.9 |
5.7 |
11/17e |
445.0 |
30.3 |
6.1 |
3.2 |
8.6 |
6.0 |
11/18e |
445.4 |
36.3 |
7.4 |
3.3 |
7.2 |
6.2 |
Note: *PBT and EPS (fully diluted) are normalised, excluding amortisation of acquired intangibles and exceptional items. Excludes disposed grass yarns business.
Weaker final quarter in Coated Technical Textiles
Year-end management guidance (20 December) pointed to a likely PBT norm outturn in the £30-31m range. (Our pre-update expectation was £31.8m, market range £31.8-33.0m.) Action taken to move older, lower-margin Coated Technical Textiles (CTT) inventory affected sales mix in the final quarter, leading to revised guidance. This suggests that H217 CTT profitability was flat to slightly down y-o-y, after a good H1 performance. As a result, we have reduced our FY17 PBT norm estimate by 4.7%. Market conditions were otherwise described as stable, although there were no further specific comments on trading in the other business units.
More detail to emerge with FY17 results
FY17 results are due to be released on 31 January and we will review group estimates more fully at that time in the context of a more detailed update. (We are aware that others may have also lowered out-year estimates although the basis for this is not clear.) We note that end-FY17 net debt is expected to be c £138m. In addition to a trading overview, we expect FY17 results to provide commentary on the previously flagged Civil Engineering business unit strategic review. With the intended departure of Brett Simpson for the CEO role at Fenner in April, results presentations are likely to be led by NED/interim CEO Trudy Schoolenberg alongside CFO Philip de Klerk (appointed in October 2017).
Valuation: Single-digit P/E, yield approaching 6%
The trading update was followed by a c 20% share price reduction on the day of the announcement, which may have reflected larger downgrades elsewhere. On our estimates, the closing year P/E and EV/EBITDA (adjusted for pensions cash and on a projected debt basis) multiples are 8.6x and 6.3x respectively. While we acknowledge that greater clarity on future prospects would be helpful, we consider that FY18 earnings are likely to show reasonable progress and, hence, generate prospective multiples below those noted for FY17 with a yield approaching 6%.
Exhibit 1: Financial summary
£m |
2014 |
2015 |
2015 |
2016 |
2017e |
2018e |
2019e |
||
Year end 30 November |
IFRS |
IFRS |
IFRS |
IFRS |
IFRS |
IFRS |
IFRS |
||
PROFIT & LOSS |
IAS19R |
IAS19R |
Restated IAS19R |
IAS19R |
IAS19R |
IAS19R |
IAS19R |
||
Revenue |
|
|
410.6 |
395.8 |
362.1 |
402.2 |
445.0 |
445.4 |
459.6 |
Cost of Sales |
N/A |
N/A |
N/A |
N/A |
N/A |
N/A |
N/A |
||
Gross Profit |
N/A |
N/A |
N/A |
N/A |
N/A |
N/A |
N/A |
||
EBITDA |
|
|
45.6 |
46.9 |
46.0 |
52.8 |
54.3 |
61.3 |
64.5 |
Operating Profit (ex SBP) |
|
|
32.3 |
33.4 |
32.5 |
35.6 |
36.1 |
42.1 |
44.3 |
Net Interest |
(5.0) |
(4.2) |
(4.3) |
(5.4) |
(4.5) |
(4.5) |
(4.3) |
||
SBP |
(0.6) |
(0.6) |
(0.6) |
(0.9) |
(1.2) |
(1.2) |
(1.2) |
||
Saudi JV |
(1.1) |
(1.8) |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
||
PNFC |
(0.4) |
(0.2) |
(0.2) |
(0.1) |
(0.1) |
(0.1) |
(0.1) |
||
Profit Before Tax (company norm) |
|
25.2 |
26.5 |
27.4 |
29.2 |
30.3 |
36.3 |
38.7 |
|
Intangible Amortisation |
(5.2) |
(4.1) |
(4.1) |
(4.0) |
(4.0) |
(4.0) |
(4.0) |
||
Exceptionals |
(3.3) |
(10.1) |
(1.9) |
0.7 |
(11) |
0 |
0 |
||
Profit Before Tax (FRS 3) |
|
|
16.7 |
12.4 |
21.4 |
25.9 |
15.7 |
32.3 |
34.7 |
Tax |
(4.9) |
(6.3) |
(6.2) |
(8.2) |
(8.6) |
(10.9) |
(11.6) |
||
Minorities |
(0.3) |
(0.5) |
(0.5) |
(0.6) |
(0.6) |
(0.6) |
(0.6) |
||
Other |
(9.0) |
(3.2) |
|||||||
Profit After Tax (norm) |
18.3 |
18.6 |
19.0 |
19.9 |
20.6 |
24.8 |
26.5 |
||
Profit After Tax (FRS 3) |
11.8 |
6.1 |
5.7 |
13.9 |
6.4 |
20.7 |
22.4 |
||
Average Number of Shares Outstanding (m) |
327.0 |
328.1 |
328.1 |
329.0 |
329.3 |
329.3 |
329.3 |
||
EPS FD- normalised (p) |
|
|
5.4 |
5.5 |
5.8 |
6.0 |
6.1 |
7.4 |
7.9 |
EPS - FRS 3 (p) |
|
|
3.5 |
1.7 |
1.7 |
5.2 |
2.0 |
6.3 |
6.8 |
Dividend per share (p) |
2.7 |
2.8 |
2.8 |
3.0 |
3.2 |
3.3 |
3.5 |
||
Gross Margin (%) |
|||||||||
EBITDA Margin (%) |
11.1 |
11.8 |
11.8 |
13.1 |
12.2 |
13.8 |
14.0 |
||
Operating Margin (before amort. and except) (%) |
7.9 |
8.4 |
8.4 |
8.9 |
8.1 |
9.5 |
9.6 |
||
BALANCE SHEET |
|||||||||
Fixed Assets |
|
|
230.2 |
232.0 |
|
261.2 |
266.1 |
272.1 |
275.1 |
Intangible Assets |
105.8 |
89.9 |
104.8 |
110.5 |
109.5 |
106.5 |
|||
Tangible Assets |
119.3 |
132.0 |
150.3 |
149.0 |
156.0 |
162.0 |
|||
Investments |
5.1 |
10.1 |
6.1 |
6.6 |
6.6 |
6.6 |
|||
Current Assets |
|
|
192.0 |
187.6 |
|
202.9 |
224.7 |
227.8 |
236.9 |
Stocks |
90.9 |
82.6 |
97.5 |
107.9 |
106.0 |
107.4 |
|||
Debtors |
62.8 |
62.9 |
70.3 |
78.8 |
77.9 |
79.4 |
|||
Other |
12.5 |
8.2 |
8.7 |
10.3 |
10.3 |
10.3 |
|||
Cash |
25.8 |
33.9 |
26.3 |
27.7 |
33.6 |
39.8 |
|||
Current Liabilities |
|
|
(87.7) |
(114.4) |
|
(88.9) |
(94.1) |
(96.9) |
(101.9) |
Creditors |
(87.7) |
(82.9) |
(88.8) |
(93.9) |
(96.9) |
(101.9) |
|||
Short term borrowings |
0.0 |
(31.5) |
(0.1) |
(0.2) |
0.0 |
0.0 |
|||
Long Term Liabilities |
|
|
(147.6) |
(133.3) |
|
(171.5) |
(194.7) |
(190.2) |
(185.7) |
Long term borrowings |
(113.8) |
(104.5) |
(137.2) |
(165.5) |
(165.5) |
(165.5) |
|||
Other long term liabilities |
(33.8) |
(28.7) |
(34.3) |
(29.2) |
(24.7) |
(20.2) |
|||
Net Assets |
|
|
186.9 |
171.9 |
|
203.6 |
202.0 |
212.9 |
224.4 |
CASH FLOW |
|||||||||
Operating Cash Flow |
|
|
34.1 |
35.3 |
|
33.9 |
29.6 |
60.6 |
59.6 |
Net Interest |
(4.5) |
(4.5) |
(4.9) |
(4.5) |
(4.5) |
(4.3) |
|||
Tax |
(7.7) |
(7.5) |
(10.8) |
(9.1) |
(10.9) |
(11.6) |
|||
Capex |
(20.2) |
(33.7) |
(22.2) |
(35.0) |
(28.0) |
(26.0) |
|||
Acquisitions/disposals |
3.0 |
0.0 |
21.7 |
5.1 |
(0.5) |
0.0 |
|||
Financing |
0 |
(1) |
(0) |
(1) |
0 |
0 |
|||
Dividends |
(8.8) |
(9.0) |
(9.2) |
(10.1) |
(10.5) |
(11.5) |
|||
Net Cash Flow |
(4.0) |
(20.2) |
8.4 |
(24.6) |
6.1 |
6.2 |
|||
Opening net debt/(cash) |
|
|
86.8 |
88.0 |
|
102.1 |
111.0 |
138.0 |
131.9 |
HP finance leases initiated |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
|||
Other |
2.8 |
6.1 |
(17.3) |
(2.4) |
0.0 |
0.0 |
|||
Closing net debt/(cash) |
|
|
88.0 |
102.1 |
|
111.0 |
138.0 |
131.9 |
125.7 |
Source: Company accounts, Edison Investment Research
|
|
International Stem Cell recently announced interim six-month results from the first cohort of four patients in its Phase I trial of ISC-hpNSC in Parkinson’s disease (PD). Positive signals were seen in a variety of measures, which include daily living, mobility, depression and compulsive disorders. The trial is continuing and the second cohort is almost enrolled, with the third patient of four recently undergoing surgical implantation. The study will enroll 12 patients at three dosing regimens (30-70m cells).